What This Label Expansion Means for Pfizer
Last month, Pfizer (NYSE: PFE) announced that the European Commission (E.C.) had authorized the company's Xeljanz immunology drug to treat adult ankylosing spondylitis -- a kind of arthritis affecting the spine and large joints -- if patients had failed at least one other therapy.
Why did the E.C. approve Xeljanz for its fifth indication in the European Union (E.U.)? And what is the sales potential of the label expansion for the pharma stock? Let's dive into these questions.
Image source: Getty Images.
Source Fool.com
